Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer’s disease: new biomarkers for diagnosis and disease progression?
Open Access
- 1 January 2021
- journal article
- editorial
- Published by Medknow in Neural Regeneration Research
- Vol. 16 (7) , 1397-1398
Abstract
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,ChinaKeywords
This publication has 11 references indexed in Scilit:
- Mild Cognitive Impairment in Clinical Practice: A Review ArticleAmerican Journal of Alzheimer's Disease and Other Dementias®, 2018
- Inflammation as a central mechanism in Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2018
- Leukocyte telomere length in mild cognitive impairment and Alzheimer's disease patientsExperimental Gerontology, 2017
- Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practiceMovement Disorders, 2016
- Telomere Shortening in Alzheimer's Disease Patients.2016
- Human telomere biology: A contributory and interactive factor in aging, disease risks, and protectionScience, 2015
- Potential Peripheral Biomarkers for the Diagnosis of Alzheimer′s DiseaseInternational Journal of Alzheimer's Disease, 2011
- An overview of biomarkers in Alzheimer′s diseaseAnnals of Indian Academy of Neurology, 2010
- Peripheral Cytokines and Chemokines in Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2009
- Expression of interleukin-18 is increased in the brains of Alzheimer's disease patientsNeurobiology of Aging, 2009